<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984045</url>
  </required_header>
  <id_info>
    <org_study_id>2018.42</org_study_id>
    <nct_id>NCT03984045</nct_id>
  </id_info>
  <brief_title>SPG Block for Acute Pediatric Migraine</brief_title>
  <official_title>Sphenopalatine Ganglion Block for Treating Acute Frontal Migraine Headache in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newark Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newark Beth Israel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2%
      lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10
      years of age presenting to a pediatric emergency department with an acute frontal migraine
      headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2%
      lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10
      years of age presenting to a pediatric emergency department with an acute frontal migraine
      headache. Excluded populations include those with sickle cell, concern for CNS infection
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacy sends down drug and placebo in study preparations for administration.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to headache resolution</measure>
    <time_frame>treatment start to patient reported resolution, up to 6 hours</time_frame>
    <description>Time to headache resolution in emergency department</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ED Length of stay</measure>
    <time_frame>Registration to discharge up to 6 hours</time_frame>
    <description>treatment to discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction: Rated on a Likert 100 millimeter scale</measure>
    <time_frame>Within 6 hours from ED registration</time_frame>
    <description>Patient satisfaction as determined by whether they would absolutely want treatment again (score=100), or would absolutely prefer another method (score = 0), or something in between (any mark along the 100 millimeter line)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hr follow up</measure>
    <time_frame>1 day</time_frame>
    <description>Presence of headache at 24 hrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment induced side effects</measure>
    <time_frame>1 day</time_frame>
    <description>Recording appearance of any side effects in ED or within 24 hr follow up, such as nausea, vomiting, neck stiffness, seizure, or prolonged (greater than 6hrs) numbness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine adequacy of blinding</measure>
    <time_frame>Asked at time of patient discharge from the emergency department or at 1 hr.</time_frame>
    <description>Determine whether treating physicians or patients can guess treatment arm (IN or IV arm) by simply asking the blinded patient and clinician which method they think the patient underwent. Measured by guessing one or the other arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Migraine in Children</condition>
  <condition>Sphenopalatine Neuralgia</condition>
  <condition>Migraine in Adolescence</condition>
  <arm_group>
    <arm_group_label>SPG block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SPG block performed by using qtip applicator soaked in 2% lidocaine and placed posteriorly into nasal cavity where it dwells for up to 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delivered through IV access obtained in all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine topical</intervention_name>
    <description>Intranasal 2% lidocaine delivered directly to SPG</description>
    <arm_group_label>SPG block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine Injection</intervention_name>
    <description>intravenous prochlorperazine at 0.15mg/kg max 10 mg</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Frontal migraine headache

        Exclusion Criteria:

          -  Non-english speaking

          -  Known pregnancy

          -  Sickle cell hemaglobinopathy

          -  Concern for CNS infection

          -  Acute febrile illness

          -  non-frontal headaches

          -  Concern for increased intracranial pressure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Sivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newark Beth Israel Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Sivitz, MD</last_name>
    <phone>973 926 2484</phone>
    <email>adam.sivitz@rwjbh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Sivitz, MD</last_name>
      <phone>973-926-2484</phone>
      <email>adam.sivitz@rwjbh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Newark Beth Israel Medical Center</investigator_affiliation>
    <investigator_full_name>Adam B Sivitz, MD</investigator_full_name>
    <investigator_title>Medical Director Pediatric Emergency Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facial Neuralgia</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

